Complexes of trypanosoma cruzi Sterol 14α-Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease: Structural basis for pathogen selectivity

Journal of Biological Chemistry

Volumn 288, Issue 44, 2013, Pages 31602-31615

  Hargrove, Tatiana Y ^a   Wawrzak, Zdzislaw ^b   Alexander, Paul W ^c   Chaplin, Jason H ^c   Keenan, Martine ^c   Charman, Susan A ^d   Perez, Catherine J ^c   Waterman, Michael R ^a   Chatelain, Eric ^e   Lepesheva, Galina I ^a,f  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MURDOCH UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e Drugs for Neglected Diseases Initiative   (Switzerland)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOLS; CODES (SYMBOLS); ENZYME ACTIVITY; IRON;

COMPARATIVE ANALYSIS; COORDINATION BONDS; DEMETHYLASE ACTIVITY; IN-VIVO EXPERIMENTS; INHIBITOR MOLECULES; METABOLIC PROPERTIES; MICROBIAL PATHOGENS; PYRIDINE DERIVATIVES;

PYRIDINE;

(4 CHLOROPHENYL) 1 [4 [4 (TRIFLUOROMETHYL)PHENYL]PIPERAZIN 1 YL] 2 (PYRIDIN 3 YL)ETHANONE; ANTIPROTOZOAL AGENT; EPL BS0967; EPL BS1246; N [4 (TRIFLUOROMETHYL)PHENYL] N [1 [5 (TRIFLUOROMETHYL) 2 PYRIDYL] 4 PIPERIDYL]PYRIDIN 3 AMINE; POSACONAZOLE; PYRIDINE DERIVATIVE; STEROL 14ALPHA DEMETHYLASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITOR INTERACTION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LIVER MICROSOME; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI;

ARALIA CORDATA; EUKARYOTA; PROTOZOA; TRYPANOSOMA CRUZI;

EID: 84887102957     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.497990     Document Type: Article

References (61)

1. Fischer, R. T., and Stam., S. H., Johnson, P. R., Ko, S. S., and Magolda., R. L., Gaylor, J. L., and Trzaskos, J. M. (1989) Mechanistic studies of lanosterol 14α-methyl demethylase: substrate requirements for the component reactions catalyzed by a single cytochrome P-450 isozyme. J. Lipid Res. 30, 1621-1632 (Pubitemid 19271057)
2. Trzaskos, J. M., and Bowen., W. D., Shafiee, A., Fischer, R. T., and Gaylor, J. L. (1984) Cytochrome P-450-dependent oxidation of lanosterol in cholesterol biosynthesis. Microsomal electron transport and C-32 demethylation. J. Biol. Chem. 259, 13402-13412 (Pubitemid 15223873)
3. Lepesheva, G. I., and Waterman, M. R. (2004) CYP51, the omnipotent P450. Mol. Cell. Endocrinol. 215, 165-170
4. Lepesheva, G. I., and Waterman, M. R. (2007) Sterol 14a-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim. Biophys. Acta 1770, 467-477 (Pubitemid 46136743)
5. Nes, W. R., and McKean, M. R. (eds) (1977) Biochemistry of Steroids and Other Isopentenoids, pp. 325-411, University Park Press, Baltimore
6. Bennett, J. E. (1974) Chemotherapy of systemic mycoses. N. Engl. J. Med. 290, 320-323
7. Vanden Bossche, H. (ed) (1988) Mode of Action of Pyridine, Pyrimidine and Azole Antifungals, pp. 79-119, Ellis Horwood Ltd., Chichester, United Kingdom
8. Maertens, J. A. (2004) History of the development of azole derivatives. Clin. Microbiol. Infect. 10, Suppl. 1, 1-10 (Pubitemid 38379948)
9. Lepesheva, G.I., Villalta, F., and Waterman, M. R. (2011) Targeting Trypanosoma cruzi sterol 14a-demethylase (CYP51). Adv. Parasitol. 75, 65-87
10. Leslie, M. (2011) Drug developers finally take aim at a neglected disease. Science 333, 933-935
11. Docampo, R., and Moreno., S. N., Turrens, J. F., Katzin, A. M., Gonzalez-Cappa, S. M., and Stoppani, A. O. (1981) Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Mol. Biochem. Parasitol. 3, 169-180
12. Beach, D.H., Goad, L. J., and Holz, G. G. (1986) Effects of ketoconazole on sterol biosynthesis by Trypanosoma cruzi epimastigotes. Biochem. Biophys. Res. Commun. 136, 851-856 (Pubitemid 16066708)
13. Urbina, J. A., Lazardi, K., Aguirre, T., Piras, M. M., and Piras, R. (1988) Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 32, 1237-1242
14. Apt, W., Aguilera, X., Arribada, A., Perez, C, Miranda, C, Sanchez, G., Zulantay, I., Cortes, P., Rodriguez, J., and Juri, D. (1998) Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am. J. Trop. Med. Hyg. 59, 133-138 (Pubitemid 28304810)
15. Araújo, M. S., Martins-Filho, O. A., Pereira, M. E., and Brener, Z. (2000) A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J. Antimicrob. Chemother. 45, 819-824 (Pubitemid 30348953)
16. Molina, J., Martins-Filho, O., Brener, Z., and Romanha., A. J., Loebenberg, D., and Urbina, J. A. (2000) Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob. Agents Chemother. 44, 150-155 (Pubitemid 30010686)
17. Urbina, J. A. (2009) Ergosterol biosynthesis and drug development for Chagas disease. Mem. Inst. Oswaldo Cruz 104, Suppl. 1, 311-318
18. Clayton, J. (2010) Chagas disease: pushing through the pipeline. Nature 465, S12-S15
19. Hucke, O., and Gelb., M. H., Verlinde, C L., and Buckner, F. S. (2005) The protein farnesyltransferase inhibitor tipifarnib as a new lead for the development of drugs against Chagas disease. J. Med. Chem. 48, 5415-5418 (Pubitemid 41209239)
20. Buckner, F. S., and Bahia., M. T., Suryadevara, P. K., White, K. L., and Shackleford., D. M., Chennamaneni, N. K., Hulverson, M. A., and Laydbak., J. U., Chatelain, E., Scandale, I., Verlinde, C. L., and Charman., S. A., Lepesheva, G. I., and Gelb, M. H. (2012) Pharmacological characterization, structural studies, and in vivo activity of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob. Agents Chemother. 56, 4914-4921
21. Buckner, F., Yokoyama, K., Lockman, J., Aikenhead, K., Ohkanda, J., Sadilek, M., Sebti, S., Van Voorhis, W., Hamilton, A., and Gelb, M. H. (2003) A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc. Natl. Acad. Sci. U.S.A. 100, 15149-15153 (Pubitemid 37518031)
22. Villalta, F., Dobish, M. C, Nde, P. N., and Kleshchenko., Y. Y., Hargrove, T. Y., Johnson, C A., Waterman, M. R., Johnston, J. N., and Lepesheva, G. I. (2013) VNI cures acute and chronic experimental Chagas disease. J. Infect. Dis. 208, 504-511
23. Roberts, C W., McLeod, R., Rice, D. W., Ginger, M., Chance, M. L., and Goad, L. J. (2003) Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol. 126, 129-142 (Pubitemid 36255612)
24. Lazardi, K., and Urbina., J. A., and de Souza, W. (1990) Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 34, 2097-2105 (Pubitemid 20373840)
25. Lepesheva, G. I., and Hargrove., T. Y., Anderson, S., Kleshchenko, Y., Furtak, V., Wawrzak, Z., Villalta, F., and Waterman, M. R. (2010) Structural insights into inhibition of sterol 14a-demethylase in the human pathogen Trypanosoma cruzi. J. Biol. Chem. 285, 25582-25590
26. Lepesheva, G. I., and Ott., R. D., Hargrove, T. Y., Kleshchenko, Y. Y., Schuster, I., and Nes., W. D., Hill, G. C, Villalta, F., and Waterman, M. R. (2007) Sterol 14a-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chem. Biol. 14, 1283-1293 (Pubitemid 350102245)
27. Lepesheva, G. I., and Hargrove., T. Y., Kleshchenko, Y., Nes, W. D., Villalta, F., and Waterman, M. R. (2008) CYP51: a major drug target in the cytochrome P450 superfamily. Lipids 43, 1117-1125
28. Soeiro Mde, N, de Souza, E. M., da Silva, C. F., Batista Dda, G., Batista, M. M., Pavão, B. P., Araújo, J. S., Aiub, C. A., da Silva, P. B., Lionel, J., Britto, C., Kim, K., Sulikowski, G., Hargrove, T. Y., Waterman, M. R., and Lepesheva, G. I. (2013) In vitro and in vivo studies of the antiparasitic activity of sterol 14a-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi. Antimicrob. Agents Chemother. 57, 4151-4163
29. Lepesheva, G. I., Zaitseva, N G., Nes, W. D., Zhou, W., Arase, M., Liu, J., Hill, G. C, and Waterman, M. R. (2006) CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase. J. Biol. Chem. 281, 3577-3585 (Pubitemid 43845975)
30. Lepesheva, G. I., and Nes., W. D., Zhou, W., Hill, G. C, and Waterman, M. R. (2004) CYP51 from Trypanosoma brucei is obtusifoliol-specific. Biochemistry 43, 10789-10799 (Pubitemid 39096721)
31. Hargrove, T. Y., Wawrzak, Z., Liu, J., Nes, W. D., and Waterman., M. R., and Lepesheva, G. I. (2011) Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14a-demethylase (CYP51) from Leishmania infantum. J. Biol. Chem. 286, 26838-26848
32. Hargrove, T. Y., Wawrzak, Z., Liu, J., Waterman, M. R., and Nes., W. D., and Lepesheva, G. I. (2012) Structural complex of sterol 14a-demethylase (CYP51) with 14a-methylenecyclopropyl-A7-24, 25-dihydrolanosterol. J. Lipid Res. 53, 311-320
33. Konkle, M. E., and Hargrove., T. Y., Kleshchenko, Y. Y., von Kries, J. P., Ridenour, W., Uddin, M. J., Caprioli, R. M., Marnett, L. J., Nes, W. D., Villalta, F., Waterman, M. R., and Lepesheva, G. I. (2009) Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14α-demethylase. J. Med. Chem. 52, 2846-2853
34. Andriani, G., Amata, E., Beatty, J., Clements, Z., and Coffey., B. J., Courtemanche, G., Devine, W., Erath, J., and Juda., C. E., Wawrzak, Z., Wood, J. T., and Lepesheva., G. I., Rodriguez, A., and Pollastri, M. P. (2013) Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth. J. Med. Chem. 56, 2556-2567
35. Lepesheva, G. I., and Park., H. W., Hargrove, T. Y., Vanhollebeke, B., Wawrzak, Z., and Harp., J. M., Sundaramoorthy, M., Nes, W. D., Pays, E., Chaudhuri, M., Villalta, F., and Waterman, M. R. (2010) Crystal structures of Trypanosoma brucei sterol 14a-demethylase and implications for selective treatment of human infections. J. Biol. Chem. 285, 1773-1780
36. Lepesheva, G. I., and Waterman, M. R. (2011) Structural basis for conservation in the CYP51 family. Biochim. Biophys. Acta 1814, 88-93
37. Lepesheva, G. I., and Waterman, M. R. (2011) Sterol 14a-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis. Curr. Top. Med. Chem. 11, 2060-2071
38. Keenan, M., and Abbott., M. J., Alexander, P. W., Armstrong, T., Best, W. M., Berven, B., Botero, A., Chaplin, J. H., and Charman., S. A., Chatelain, E., von Geldern, T. W., Kerfoot, M., Khong, A., Nguyen, T., McManus, J. D., Morizzi, J., Ryan, E., Scandale, I., Thompson, R. A., Wang, S. Z., and White, K. L. (2012) Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. J. Med. Chem. 55, 4189-4204
39. Keenan, M., and Alexander., P. W., Diao, H, and Best., W. M., Khong, A., Kerfoot, M., Thompson, R. C, White, K. L., and Shackleford., D. M., Ryan, E., Gregg, A. D., and Charman., S. A., von Geldern, T. W., Scandale, I., and Chatelain, E. (2013) Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. Bioorg. Med. Chem. 21, 1756-1763
40. Buckner, F. S., and Verlinde., C. L., La Flamme, A. C, and Van Voorhis, W. C. (1996) Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing β-galactosidase. Antimicrob. Agents Chemother. 40, 2592-2597 (Pubitemid 26367650)
41. Lepesheva, G. I., Virus, C, and Waterman, M. R. (2003) Conservation in the CYP51 family. Role of the B' helix/BC loop and helices F and G in enzymatic function. Biochemistry 42, 9091-9101 (Pubitemid 36935417)
42. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378
43. Bui, S. H, McLean, K. J., and Cheesman., M. R., Bradley, J. M., Rigby, S. E., and Levy., C. W., Leys, D., and Munro, A. W. (2012) Unusual spectroscopic and ligand binding properties of the cytochrome P450-flavodoxin fusion enzyme XplA. J. Biol. Chem. 287, 19699-19714
44. Leslie, A. (2006) The integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 62, 48-57
45. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763
46. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501
47. Vagin, A. A., and Steiner., R. S., Lebedev, A. A., Potterton, L., McNicholas, S., Long, F., and Murshudov, G. N. (2004) REFMAC5 dictionary: organisation of prior chemical knowledge and guidelines for its use. Acta Crystallogr. D Biol. Crystallogr. 60, 2284-2295
48. Guengerich, F. P. (2006) Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 8, E101-E111
49. Lepesheva, G. I., and Podust., L. M., Bellamine, A., and Waterman, M. R. (2001) Folding requirements are different between sterol 14α-demethylase (CYP51) from Mycobacterium tuberculosis and human or fungal orthologs. J. Biol. Chem. 276, 28413-28420
50. Hargrove, T. Y., Kim, K., de Nazaré Correia Soeiro, M., da Silva, C. F., Batista, D. D., Batista, M. M., Yazlovitskaya, E. M., Waterman, M. R., Sulikowski, G.A., and Lepesheva, G.I. (2012) CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds. Int. J. Parasitol. Drugs Drug Resist. 2, 178-186
51. Correia, M. A., and Ortiz de Montellano, P. R. (2005) Inhibition of cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano, P. R., ed) pp. 246-322, Plenum Publishing Corp., New York
52. Zhang, W., Ramamoorthy, Y., Kilicarslan, T., Nolte, H., and Tyndale., R. F., and Sellers, E. M. (2002) Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug. Metab. Dispos. 30, 314-318 (Pubitemid 34175023)
53. Obach, R. S., and Walsky., R. L., Venkatakrishnan, K., Gaman, E. A., and Houston., J. B., and Tremaine, L. M. (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther. 316, 336-348 (Pubitemid 41832613)
54. Schuster, I., and Bernhardt, R. (2007) Inhibition of cytochromes P450: existing and new promising therapeutic targets. Drug. Metab. Rev. 39, 481-499 (Pubitemid 47355725)
55. Saari, T. I., and Olkkola, K. T. (2010) Azole antimycotics and drug interactions in the perioperative period. Curr. Opin. Anaesthesiol. 23, 441-448
56. Gubbins, P. O. (2011) Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450. Expert Opin. Drug. Metab. Toxicol. 7, 1411-1429
57. Mast, N., Zheng, W., Stout, C. D., and Pikuleva, I. A. (2013) Antifungal azoles: structural insights into undesired tight binding to cholesterol- metabolizing CYP46A1. Mol. Pharmacol. 84, 86-94
58. Kanafani, Z. A., and Perfect, J. R. (2008) Resistance to antifungal agents: mechanisms and clinical impact. Clin. Infect. Dis. 46, 120-128 (Pubitemid 351263573)
59. Espinel-Ingroff, A. (2008) Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev. Iberoam. Micol. 25, 101-106 (Pubitemid 351798337)
60. Dobish, M. C., Villalta, F., Waterman, M. R., and Lepesheva., G. I., and Johnston, J. N. (2012) Organocatalytic, enantioselective synthesis of VNI: a robust therapeutic development platform for Chagas, a neglected tropical disease. Org. Lett. 14, 6322-6325
61. Strushkevich, N., and Usanov., S. A., and Park, H. W. (2010) Structural basis of human CYP51 inhibition by antifungal azoles. J. Mol. Biol. 397, 1067-1078